Changa

# Research Output: Changa

## Botanical Identity

Changa is a **preparation**, not a botanical species. The brief's seed data correctly classifies it as type "preparation." There is no accepted binomial, family, or native range for Changa itself. It is a smokeable blend in which extracted DMT (N,N-dimethyltryptamine) is infused onto a base of MAOI-containing plant material [Ref 27].

### Component Plants

**MAOI source plants (one or more per blend):**

1. **Banisteriopsis caapi** — family Malpighiaceae; a woody liana native to the Amazon River basin. Provides harmine, harmaline (tetrahydro-β-carboline), and tetrahydroharmine (THH) as MAO-A inhibitors [Ref 7]. Alkaloid content documented in multiple samples from Peru (McKenna et al. 1984 [Ref 7]; Wang et al. 2010 [Ref 17]).

2. **Peganum harmala** (Syrian rue) — family Nitrariaceae; native to the Middle East, Central Asia, and Mediterranean. Seeds contain harmine (53.13%) and harmaline (39.12%) as dominant alkaloids (Sunil & P.A. 2025 [Ref 14]). Not a traditional Amazonian plant; inclusion in Changa is a modern cross-cultural synthesis.

**DMT source plants (used to produce extracted freebase DMT):**
- *Psychotria viridis* (chacruna) — leaves contain DMT; traditional Amazonian admixture plant.
- *Mimosa tenuiflora* (formerly *M. hostilis*) — root bark is a popular DMT extraction source.
- *Acacia confusa* and related species.
Note: The specific DMT source is not a fixed component of changa; only the extracted freebase DMT is incorporated into the blend.

**Other admixture herbs** — Wildly variable by recipe: blue lotus (*Nymphaea caerulea*), wild dagga (*Leonotis leonurus*), passionflower (*Passiflora* spp.), mullein, calea, and many others. These contribute to the flavour, smoking properties, and possibly minor pharmacological effects but are not universally standardized [Ref 27].

### Botanical Identity Note
Because Changa is a preparation, the "Botanical Identity" section of the article should open by establishing this clearly, then describe the major component plants (B. caapi and P. harmala as MAO sources; various DMT-source plants). There is no single authoritative taxonomy to verify. The brief's seed data showing no botanical family/genus is accurate for a preparation-type entry.

---

## Alkaloid / Cannabinoid Profile

Changa contains two pharmacologically distinct alkaloid classes in combination:

### 1. Primary Psychedelic: DMT (N,N-Dimethyltryptamine)
- **PubChem CID**: 6089
- **IUPAC**: 2-(1H-indol-3-yl)-N,N-dimethylethanamine
- **Molecular formula**: C₁₂H₁₆N₂; **MW**: 188.27 g/mol; **InChIKey**: DMULVCHRPCFFGV-UHFFFAOYSA-N
- **Typical content in Changa blend**: 25–50% by weight [Ref 27]; Julian Palmer's own formulation reportedly ~25% DMT, equivalent to approximately 250 mg DMT per gram of blend [Ref 37].
- No systematic HPLC or GC-MS quantification studies of commercially prepared Changa samples exist in the published literature. Concentrations are derived from user-reported preparation ratios and anecdotal accounts.

### 2. MAOI Component: β-Carboline Alkaloids

All three primary harmala alkaloids act as **reversible MAO-A inhibitors** (rMAO-A inhibitors). McKenna et al. (1984 [Ref 7]) established that their inhibitory effects are additive, not synergistic.

**Harmine**
- **PubChem CID**: 5280953
- **Molecular formula**: C₁₃H₁₂N₂O; **MW**: 212.25 g/mol; **InChIKey**: BXNJHAXVSOCGBA-UHFFFAOYSA-N
- Dominant alkaloid in both *B. caapi* and *P. harmala* (53.13% of P. harmala seed extract by GC-MS [Ref 14]).
- Potent MAO-A inhibitor; also documented to stimulate adult neurogenesis in vitro (Morales-García et al. 2017 [Ref 34]).

**Harmaline**
- **PubChem CID**: 3564
- **Molecular formula**: C₁₃H₁₄N₂O; **MW**: 214.26 g/mol; **InChIKey**: RERZNCLIYCABFS-UHFFFAOYSA-N
- 39.12% of *P. harmala* seed extract by GC-MS (Sunil & P.A. 2025 [Ref 14]).
- Strong MAO-A inhibitor; identified as the most pharmacologically problematic alkaloid in preclinical safety models (White et al. 2024 [Ref 6]).
- Produces generalized tremor in animals — the canonical experimental model of essential tremor (Lavița et al. 2016 [Ref 19]).
- Cerebellar Purkinje cell degeneration documented at high doses in rats (O'Hearn & Molliver 1993 [Ref 20]).

**Tetrahydroharmine (THH)**
- **PubChem CID**: 442118
- **Molecular formula**: C₁₃H₁₆N₂O; **MW**: 216.28 g/mol; **InChIKey**: ZXLDQJLIBNPEFJ-MRVPVSSYSA-N
- Weaker MAO-A inhibitor than harmine/harmaline; also documented as a serotonin reuptake inhibitor.
- Primarily found in *B. caapi*; substantially lower in *P. harmala*.

### Concentration Variability
Quantified alkaloid concentrations in ayahuasca preparations (HPLC-DAD): DMT 402–2070.3 µg/mL; harmaline 27.5–181.3 µg/mL; harmine 294.5–2893.8 µg/mL; THH 849.5–2052.5 µg/mL (Lanaro et al. 2015 [Ref 31]). **No published quantification studies exist specifically for Changa as a preparation** — these ayahuasca data are provided for context only. Changa batch-to-batch variability is expected to be substantially higher, as it is prepared informally without standardization.

### Preparation Method and Constituent Ratio Effects
The standard preparation method involves dissolving freebase DMT in a volatile solvent (e.g., isopropyl alcohol or naphtha), pouring this solution over the chosen herb blend, and allowing the solvent to evaporate [Ref 27, 37]. This cold-infusion method preserves all alkaloids in their freebase form, optimizing volatilization and inhalation. Unlike oral ayahuasca, there is no aqueous extraction step; no decarboxylation is needed (DMT is already freebase).

The proportion of MAOI herb to DMT determines the ratio of MAO inhibition to psychedelic load. Higher proportions of MAOI material relative to DMT content extend duration and subjective intensity. No published pharmacokinetic study has examined the smoked DMT + MAOI combination specifically as Changa.

---

## History & Ethnobotany

### Origin of Changa as a Preparation
Changa was developed by **Julian Palmer**, an Australian psychonaut, in the **late 1990s** and first named in **2003–2004** [Ref 27, 28, 37]. According to Palmer's own account, he coined the name "changa" during an ayahuasca ceremony, and the word has no specific linguistic meaning in his account. Palmer's stated motivation was to create a gentler, more accessible format for DMT inhalation — one that reduced the abruptness and disorientation associated with smoking pure freebase DMT, and that could be administered in a joint/bong format rather than a glass pipe [Ref 37].

From the **mid-2000s** onward, Palmer introduced Changa at festivals and gatherings across Australia, Europe, Asia, Africa, and South America, and it spread rapidly through psychedelic subcultures, primarily via informal networks and the internet [Ref 27].

**No peer-reviewed publication documents Changa's origin or spread.** The historical record rests primarily on Palmer's personal website, online community forums, and secondary coverage by harm-reduction media. The only academic literature that even peripherally references Changa-like preparations describes the broader category of "smokable DMT with MAOI additives" in the context of novel psychoactive substance (NPS) review articles [Ref 12].

### Relationship to Ayahuasca Tradition
Changa is explicitly modelled on the ayahuasca pharmacological principle — combining DMT with beta-carboline MAOIs — but adapts it for the inhalation route [Ref 27]. Traditional Amazonian ayahuasca has well-documented ethnobotanical literature going back to Richard Evans Schultes' fieldwork in the mid-20th century and earlier accounts from Western explorers. Ayahuasca is prepared by boiling *Banisteriopsis caapi* bark and DMT-containing plant admixtures (most commonly *Psychotria viridis*) in water. McKenna et al. (1984 [Ref 7]) provided the first rigorous quantitative analysis confirming the MAO inhibition mechanism.

Changa's use of *Peganum harmala* (Syrian rue) as an MAOI alternative to *B. caapi* is a non-traditional, pragmatic substitution driven by *P. harmala*'s wider availability and higher alkaloid concentration. This cross-cultural synthesis has no traditional antecedent.

### Timeline
- **1984**: McKenna et al. establish MAOI mechanism of ayahuasca pharmacology [Ref 7]
- **Late 1990s**: Palmer develops early Changa blends in Australia [Ref 37]
- **2003–2004**: Palmer coins "changa" during an ayahuasca ceremony [Ref 27, 28]
- **Mid-2000s**: International spread through festival circuits [Ref 27]
- **2010s**: Changa appears in harm-reduction literature and online databases (PsychonautWiki, Erowid)
- **2015**: Riba et al. [Ref 1] document smoked DMT pharmacology in humans (most relevant academic parallel)
- **2025**: Clinical trials of vaporized DMT demonstrate safety and efficacy [Ref 24, 25]

**Flag for human review**: Changa's history section relies entirely on non-peer-reviewed sources. The generation agent should frame this as documented community history with appropriate confidence framing, not as established academic fact.

---

## Neuroscience & Mechanism

### Primary Receptor Targets

**DMT:**
- **5-HT₂A receptor**: Primary target; DMT confirmed as full agonist at 5-HT₂A and partial agonist at 5-HT₂C in native preparations (Smith et al. 1998 [Ref 15]). This receptor mediates the psychedelic, hallucinatory, and perceptual effects.
- **5-HT₁A receptor**: Additional serotonergic agonist activity.
- **Sigma-1 receptor (SIGMAR1)**: Activated by DMT; promotes neuroprotection, neuroplasticity, memory processes (Inserra 2018 [Ref 33]; Frecska et al. 2016 [Ref 35]).
- **Trace Amine-Associated Receptor 1 (TAAR1)**: Emerging evidence for agonist activity (Egger et al. 2024 [Ref 5]).
- **Comprehensive review**: Egger et al. (2024 [Ref 5]) synthesize current understanding of DMT's multi-receptor pharmacology.

**Beta-carboline alkaloids:**
- **MAO-A inhibition (reversible)**: Harmine and harmaline are potent reversible MAO-A inhibitors; THH is a weak MAO-A inhibitor and serotonin reuptake inhibitor (McKenna et al. 1984 [Ref 7]).
- **Neurogenesis stimulation**: Harmine, THH, harmaline, and harmol stimulate adult neural stem cell proliferation, migration, and differentiation in mice (Morales-García et al. 2017 [Ref 34]).
- **Anti-inflammatory**: B. caapi components reduce proinflammatory cytokine production in microglial cells (Santos et al. 2022 [Ref 3 — note: PMID 35458698 in original results, not formally numbered in registry]).

### CNS Mechanism in Changa
When Changa is smoked, three processes occur in sequence:

1. **DMT vaporizes** and is rapidly absorbed across the pulmonary epithelium, bypassing hepatic first-pass metabolism. In the smoked route, MAO-dependent metabolism shifts to CYP-dependent pathway: the IAA/DMT-NO ratio falls, unmetabolized DMT and DMT-N-oxide rise (Riba et al. 2015 [Ref 1]). This shift underlies psychoactivity.

2. **Beta-carbolines co-inhale** and are absorbed simultaneously, providing local MAO-A inhibition in the lungs and systemic inhibition. This prevents the rapid MAO-mediated breakdown of DMT, extending plasma half-life and CNS exposure. PBPK modelling confirms harmine reduces DMT metabolism in liver and lungs (Wittayakarn et al. 2025 [Ref 39]).

3. **Combined effect**: Extended and potentiated DMT activity compared to freebase DMT alone. The Egger et al. (2025 [Ref 8]) factorial dose-escalation study of transmucosal DMT + harmine demonstrates that harmine reduces DMT metabolism while DMT alters harmine PK (bidirectional interaction), with combined effects lasting 4–5 h at oral/transmucosal doses; the smoked Changa format is expected to produce a shorter but comparably potentiated experience.

### Neuroimaging and Brain Activity
For ayahuasca (the closest studied analogue), neuroimaging shows:
- Increased delta and theta oscillations in amygdala and hippocampus
- Decreased alpha wave activity in the default mode network (DMN)
- Stimulation of visual-association cortex (James et al. 2022 [Ref 9])
- Post-acute: increased PCC–ACC connectivity correlating with mindfulness-related changes (Sampedro et al. 2017 [Ref from OpenAlex search])

No neuroimaging studies exist for Changa specifically.

### Pharmacokinetics by Route

**Smoked DMT (freebase, without MAOI — closest published analogue):**
- Rapid pulmonary absorption: onset within 15–45 seconds
- Peak plasma effects: ~2–5 minutes post-inhalation
- Duration: 5–15 minutes
- In Riba et al. (2015 [Ref 1]) 25 mg smoked DMT: fully psychoactive; urinary DMT-N-oxide 28%, unmetabolized DMT 10%, IAA 63%

**Smoked Changa (DMT + MAOI, no published formal PK study):**
- Onset: ~1–2 minutes (consistent with inhalation route; slightly delayed vs. freebase due to herb combustion dynamics)
- Peak: ~5–15 minutes
- Duration: reported 15–40 minutes (extended vs. freebase by MAOI effect) [Ref 27]
- **FLAG**: No published pharmacokinetic data exist for smoked Changa specifically. Duration data are derived from user reports and community sources only.

**Comparative routes (for context):**
- IV DMT (Strassman 1994 [Ref 3]): onset immediate, peak 90–120 seconds, resolved by 30 minutes
- Oral ayahuasca (Riba et al. 2003 [Ref 2]): Tmax 1.5 h, peak effects 1.5–2 h, duration ~4 h; DMT Cmax 12–17 ng/mL
- Transmucosal DMT + harmine (Egger et al. 2025 [Ref 8]): effects lasted 4–5 h; peak DMT Cmax 33 ng/mL
- Vaporized inhaled DMT (clinical): 10–20 min duration (Falchi-Carvalho et al. 2025 [Ref 24])

**CYP enzyme involvement:**
- DMT metabolism: CYP2D6 primary in smoked route; MAO-A primary in oral route (Riba et al. 2015 [Ref 1])
- Harmine metabolism: CYP2D6 also involved; CYP2D6 inhibitors (fluoxetine, paroxetine) markedly increase harmine and DMT exposure (Ribeiro et al. 2026 [Ref 18])
- PBPK modelling: Wittayakarn et al. (2025 [Ref 39]) developed validated models for DMT and harmine PK across routes

---

## Effects & Dose by Preparation

### Preparation: Smoked Changa (inhalation)

**Dose ranges** (community-documented; no published human dose-finding studies for Changa specifically):
- **Threshold**: ~10–15 mg DMT content in preparation
- **Light**: ~15–25 mg DMT content
- **Common**: ~25–50 mg DMT content (typically "one bong bowl" [Ref 27])
- **Strong**: ~50–100 mg DMT content
- **Total preparation weight** smoked per session: typically 50–200 mg of the herb blend (at 25–50% DMT content)

**⚠️ FLAG for human review**: All dose ranges above are derived from community/harm-reduction sources (Erowid [Ref 36], PsychonautWiki [Ref 27]) and Julian Palmer's own account [Ref 37]. No peer-reviewed dose-finding study for Changa exists. These values have not been verified against a published source or Curiosity v1 DB record.

**Onset**: ~1–2 minutes post-inhalation [Ref 27]
**Peak**: ~5–15 minutes
**Duration**: ~15–40 minutes (vs. 5–15 minutes for pure freebase DMT) [Ref 27]
**Total experience**: typically 20–45 minutes

**Note on preparation: oral MAOI pre-loading + vaporized DMT**
An alternative administration method documented in community sources [Ref 27] involves orally ingesting MAOI (P. harmala seeds or B. caapi extract) 30–60 minutes before vaporizing DMT. This produces effects more similar to ayahuasca in duration (1–4 hours) and is sometimes called a "pharmahuasca" approach. This method is distinct from smoking Changa but uses the same pharmacological principle.

### Subjective Effects
Published studies of smoked/inhaled DMT and IV DMT (the closest studied analogues) describe:
- **Perceptual**: Vivid visual geometry, kaleidoscopic patterns, complex internal hallucinations, external visual distortions including object transformations, entity contact (Strassman 1994 [Ref 3])
- **Cognitive**: Intense ego dissolution, loss of control of thought, profound strangeness and novelty
- **Temporal**: Time cessation or extreme distortion
- **Emotional**: Euphoria, awe, terror, emotional lability, catharsis
- **Transpersonal**: Entity encounters, near-death experiences, feelings of dying and rebirth, non-dual awareness

Changa's MAOI component is widely reported in community accounts to produce a **more coherent and less overwhelming** experience than freebase DMT alone — the onset is less abrupt, the peak is less "blasted out," and users retain greater situational awareness [Ref 27, 37]. This is consistent with the extended pharmacokinetic profile produced by MAO-A inhibition.

**Dose-response**: In the IV DMT dose-response study (Strassman 1994 [Ref 3]), threshold perceptual effects occurred at 0.05 mg/kg IV; full psychedelic effects at 0.2–0.4 mg/kg IV. Smoked doses in community use range from 10–60 mg with effects scaling accordingly. No controlled dose-response data exist for Changa.

**Effect modifiers**: 
- MAOI plant species and concentration significantly alter intensity and duration
- DMT:MAOI ratio in the blend (variable)
- Breath-holding technique (longer hold increases absorption from smoke)
- Setting and mindset (strong determinant per psychedelic literature generally)
- Prior tolerance state (DMT has functional tolerance but this resolves quickly between sessions)

---

## Safety & Toxicity

### Toxicology Overview
Ayahuasca (DMT + harmala alkaloids, oral) is characterized as generally safe in healthy populations in controlled settings (White et al. 2024 [Ref 6]). No LD₅₀ data for DMT in humans exist. Animal model LD₅₀ values for individual components are not available in the reviewed literature.

No adverse event case reports specifically attributing harm to **Changa as a preparation** were found in the published literature. All adverse event data below are extrapolated from ayahuasca and smoked/IV DMT studies.

### Acute Adverse Effects
**Cardiovascular**: IV DMT produces dose-dependent increases in heart rate, blood pressure, pupil dilation, and rectal temperature (Strassman & Qualls 1994 [Ref 4]). Ayahuasca oral route increases diastolic BP by ~9 mmHg at high doses (Riba et al. 2003 [Ref 2]).

**Neurological**: Overwhelming, terrifying psychedelic experiences ("bad trips") are the primary adverse effect. From the Global Ayahuasca Survey (n=10,836): acute physical adverse effects (primarily vomiting) in 69.9%; mental health adverse effects in following weeks/months in 55.9% (Bouso et al. 2022 [Ref 16]). However, 88% of those with mental health effects considered them part of a positive process. Only 2.3% required medical attention.

**Serious adverse events** (rare, case reports):
- Rhabdomyolysis with acute kidney injury (CK 110,659 IU/L; creatinine 13.6 mg/dL) following ayahuasca use, attributed to catecholaminergic surge, hyperactivity, and dehydration (Kermanshah et al. 2025 [Ref 13]).
- Serotonin toxicity-like syndromes and cardiovascular events have been reported with ayahuasca in uncontrolled settings (White et al. 2024 [Ref 6]).

**Beta-carboline-specific concerns:**
- High-dose harmaline: Purkinje cell degeneration in rat cerebellar vermis via inferior olive excitotoxicity (O'Hearn & Molliver 1993 [Ref 20]).
- Beta-carbolines are tremorogenic; harmaline administration is the standard animal model of essential tremor (Lavița et al. 2016 [Ref 19]). Human relevance at Changa doses is unclear.
- Harmaline identified as most problematic alkaloid in preclinical models (White et al. 2024 [Ref 6]).
- **FLAG**: Purkinje cell degeneration data are from rats receiving high parenteral doses of harmaline. Direct human relevance at smoked Changa doses is not established.

### Drug Interactions

**Serotonin syndrome risk (high severity — mechanism-based)**:
- **SSRIs and SNRIs**: Beta-carbolines inhibit MAO-A, potentiating serotonergic activity. Concurrent SSRI use risks serotonin syndrome. PBPK modelling confirms that fluoxetine and paroxetine (CYP2D6 inhibitors) markedly increase DMT and harmine plasma levels (Ribeiro et al. 2026 [Ref 18]). Systematic review found SSRIs among the most concerning interactions for psychedelics generally (Halman et al. 2024 [Ref 11]).
- **MAOIs (irreversible)**: Combining Changa with any irreversible MAOI (phenelzine, tranylcypromine, selegiline) is potentially life-threatening due to compounded MAO inhibition and serotonergic surge.
- **Tramadol**: Serotonin reuptake inhibition + possible MAO interaction → serotonin syndrome risk.
- **Triptans**: Serotonergic agonists; possible additive risk.
- **Lithium**: Case reports of seizures with combination of lithium and psychedelics; mechanism unclear.

**Tyramine (cheese reaction)**:
- Beta-carbolines as MAO-A inhibitors theoretically inhibit dietary tyramine metabolism, potentially causing hypertensive crisis. However, reversible MAO-A inhibitors (rMAOI) such as harmine/harmaline carry substantially lower tyramine risk than irreversible MAOIs [Ref 18]. The clinical significance at smoked Changa doses is not formally established in the literature.
- **FLAG**: No clinical case reports of hypertensive crisis from tyramine in the context of Changa or harmaline-containing preparations were found. This remains a theoretical mechanism-based concern.

**Mechanism-based interactions summary**: All interaction severity flags above are supported by CYP-mediated pharmacokinetic mechanism and/or serotonergic pharmacodynamic mechanism. No clinical case reports specifically for Changa were found.

### Tolerance and Dependence
- **Tolerance**: Classical psychedelics at 5-HT₂A receptors develop rapid functional tolerance within a session; tolerance between sessions is generally absent for infrequent use (Strassman 1994 [Ref 3]). Smith et al. (1998 [Ref 15]) note profound desensitization at 5-HT₂C but not 5-HT₂A, consistent with DMT's lack of functional tolerance in humans. **No published tolerance studies for Changa specifically exist.**
- **Dependence**: No evidence of physical dependence on DMT or ayahuasca. Psychological dependence risk appears low (White et al. 2024 [Ref 6]). DMT is not associated with compulsive use patterns in the literature.
- **Cross-tolerance**: Cross-tolerance exists between DMT and other classical psychedelics (psilocybin, LSD) via shared 5-HT₂A mechanisms.
- **Withdrawal**: No documented withdrawal syndrome for DMT or ayahuasca.

### Reproductive Toxicity
Ayahuasca at 4–8× human doses in rats (oral, GD 6–20) caused maternal deaths, kidney injury, neuronal loss in hippocampus/raphe nuclei, and fetal anomalies. Non-lethal doses increased embryolethality and soft-tissue anomalies (da Motta et al. 2018 [Ref 21]). **Changa is contraindicated during pregnancy.** Caution warranted despite extrapolation limitations from high-dose rat data.

### Contamination / Adulterant Risk
No published studies on contamination of Changa preparations were found. As an informally produced preparation:
- **DMT source purity**: Variable. Home extractions may contain residual solvents (naphtha, etc.).
- **Mislabelling of MAOI content**: No standardization; actual harmine/harmaline content undisclosed.
- **Herb blend substitution**: Plants used as base may vary significantly; misidentified herbs are a theoretical concern.
- **No commercially standardized Changa products** have been subjected to published independent assay.
- **FLAG**: No published contamination or adulterant data specific to Changa exist.

### Drug Detection
- Standard immunoassay drug screens (workplace panels) do not typically screen for DMT or beta-carboline alkaloids.
- Specialized GC-MS or LC-MS/MS can detect DMT, harmine, harmaline, and their metabolites in urine (Yritia et al. 2002 [Ref 38]).
- DMT urinary detection: unmetabolized DMT present after smoked route (Riba et al. 2015 [Ref 1]); primary metabolite IAA (indole-3-acetic acid) is a common endogenous compound and non-specific.
- **FLAG**: No published studies on standard drug screening sensitivity for smoked Changa alkaloids found.

---

## Harm Reduction

Published harm reduction data specific to Changa are absent from the peer-reviewed literature. The following is synthesized from analogous sources:

- **Avoid combinations with SSRIs, SNRIs, irreversible MAOIs, tramadol, triptans, and lithium** — serotonin syndrome risk [Ref 11, 18].
- **Dietary considerations with MAOI component**: Although reversible MAOIs carry lower tyramine risk than irreversible ones, avoiding high-tyramine foods (aged cheese, cured meats, fermented products) is a common precautionary recommendation in the community. Not formally validated for Changa doses.
- **Set and setting**: As with all psychedelics, the subjective experience is strongly modulated by mindset and environment.
- **Sitting position**: Changa should be used seated or lying down given rapid-onset motor impairment.
- **Companion presence**: Recommended for inexperienced users given intensity and disorientation.
- **Dose titration**: The MAOI component makes it difficult to titrate dose experience precisely; users are advised to start with a small amount of a standardized preparation.
- **Vaporization temperature**: Recommended 60–80°C for optimal vaporization without combustion (community sources [Ref 27]).
- **Testing**: Reagent testing for DMT content (Ehrlich's reagent turns purple with indoles) is available but does not quantify or verify MAOI content.

---

## Legal Status

### DMT (N,N-Dimethyltryptamine) — Active Psychedelic Component

| Jurisdiction | Status |
|---|---|
| United States (Federal) | Schedule I controlled substance (Controlled Substances Act 1970, placed 1971). No accepted medical use. [Ref 29] |
| United States (State) | Oregon Measure 110 (2020) decriminalized possession for personal use. Some cities have passed symbolic decriminalization (Denver, etc.). No state has legalized recreational DMT. |
| United Kingdom | Class A drug under the Misuse of Drugs Act 1971. Maximum 7 years for possession, life for supply. |
| Canada | Schedule III, Controlled Drugs and Substances Act. Religious exemptions granted to some organizations (e.g., Santo Daime). |
| Australia | Schedule 9 (Prohibited Substance) under Therapeutic Goods Administration (TGA) Poisons Standard. |
| Netherlands | List I substance (Opiumwet). |
| Germany | Controlled under the Betäubungsmittelgesetz (BtMG). |
| International | Schedule I, UN Convention on Psychotropic Substances (1971). Organic plant materials containing DMT and traditional ayahuasca brew are not explicitly regulated under this convention, creating legal ambiguity for plant sources. |

**Religious/ceremonial exemptions**: Several ayahuasca churches (Santo Daime, União do Vegetal) have received legal exemptions in the US, Canada, and the Netherlands for sacramental use. These do not apply to Changa as a smoked preparation.

### Banisteriopsis caapi (MAOI plant)
- **United States**: Not a DEA-scheduled substance. The plant itself is legal to cultivate and possess; however, preparations intended for human consumption of its psychoactive constituents fall in a legal grey area.
- **Other jurisdictions**: Generally not scheduled, though its alkaloids (harmine, harmaline) may be controlled in some European countries.

### Peganum harmala / Harmala Alkaloids
- **United States**: Not DEA-scheduled. Seeds are legally sold. USDA restricted importation as of March 2022 [Ref 30]. Louisiana Act No. 159 (effective August 2005) prohibits for human consumption.
- **State regulations**: AZ, CA, CO, NV, NM, OR restrict P. harmala cultivation as an invasive species.
- **Harmaline**: Controlled in some European countries (e.g., Hungary, Latvia). Not explicitly scheduled by UN conventions.

### Changa as a Preparation
Because Changa contains DMT — a Schedule I controlled substance in the US and Schedule I under the 1971 UN Convention — **the preparation itself is illegal in all jurisdictions where DMT is controlled**, regardless of the legal status of the MAOI or admixture herbs.

**FLAG (low confidence)**: Legal status for harmaline and harmine in individual EU member states requires country-by-country verification. The research agent has moderate confidence for US and UK status but lower confidence for EU member state details and Australia's specific handling of B. caapi and P. harmala.

---

## Clinical Trials

The following trials involve inhaled/vaporized DMT (the closest clinical analogue to Changa):

1. **NCT04640831** — "Safety of GH001 in Healthy Volunteers" | GH Research Ireland Limited | Phase 1 | COMPLETED | Inhaled DMT fumarate (GH001)
2. **NCT05163691** — "Pharmacokinetics of GH001 in Healthy Volunteers" | GH Research Ireland Limited | Phase 1 | COMPLETED
3. **NCT04698603** — "Clinical Study of GH001 in Depression" | GH Research Ireland Limited | Phase 1/2 | COMPLETED | TRD/MDD
4. **NCT05800860** — "A Trial of GH001 in Patients With Treatment-resistant Depression" | GH Research Ireland Limited | Phase 2 | COMPLETED
5. **NCT06094907** — "Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression" | UFRN Brazil | Phase 2 | COMPLETED → Published as Falchi-Carvalho et al. 2025 [Ref 24]: vaporized DMT 15 mg and 60 mg; 85.71% response rate; 57.14% remission at day 7
6. **NCT05573568** — "Clinical Study of DMT in Healthy Adults" | Biomind Labs Inc. | Phase 1 | COMPLETED
7. **NCT06511947** — "Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects" | GH Research Ireland Limited | Phase 1 | RECRUITING (as of data cutoff)
8. **NCT07540494** — "Pharmacokinetics and Safety of GH001 Via Aerosol Delivery" | GH Research Ireland Limited | Phase 1 | NOT YET RECRUITING

**Note**: No clinical trials have used Changa specifically. GH001 is a proprietary pharmaceutical-grade inhaled DMT fumarate formulation, not a herbal blend. These trials are included because they are the closest studied clinical analogue to Changa's inhalation route.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Skip per instructions.

---

## Gaps & Flags

### Critical Data Gaps

1. **No published pharmacokinetic data for Changa as a preparation**: Smoked DMT + MAOI combination PK has never been formally studied. All duration/onset/peak data are extrapolated from pure smoked DMT (Riba 2015 [Ref 1]), IV DMT (Strassman 1994 [Refs 3–4]), and oral ayahuasca studies (Riba 2003 [Ref 2]).

2. **No dose-finding studies for Changa**: ⚠️ All dose values in the "Effects & Dose" section are **not verified against any published source**. They are derived from community documentation (Erowid [Ref 36], PsychonautWiki [Ref 27], Palmer [Ref 37]). **These must be flagged for human editorial review before inclusion in structured DB records.**

3. **No adverse event case reports attributed specifically to Changa**: The safety section extrapolates from ayahuasca, IV DMT, and smoked DMT literature. The risk profile may differ meaningfully given the smoked route and MAOI co-inhalation.

4. **No chemical analysis studies of Changa samples**: DMT content (25–50%) is reported by users/community, not laboratory quantification.

5. **Changa not indexed in academic literature under this name**: PubMed returns zero results for "changa" as a drug preparation. All pharmacological foundations rest on ayahuasca and DMT constituent literature.

### Interaction Flags

6. **Tyramine/cheese reaction**: Mechanism-based concern (MAO-A inhibition by harmine/harmaline) but no clinical case reports in Changa or harmaline-containing preparation context. **Severity not backed by clinical case report** — flag for editorial decision on inclusion.

7. **Harmaline cerebellar neurotoxicity**: Documented in rats at parenteral high doses. Human relevance at smoked Changa doses is unknown. **Do not extrapolate rat data directly to humans without caveat.**

8. **SSRI/MAOI interaction**: This IS backed by mechanistic (CYP2D6-mediated) pharmacokinetic data (Ribeiro et al. 2026 [Ref 18]) and pharmacodynamic serotonergic mechanism. Severity: high.

### Traditional-Use Flag

9. **History section relies entirely on non-peer-reviewed sources**: Julian Palmer's accounts [Refs 27, 28, 37] are the only available documentation of Changa's origin. **Flag for human editorial review.**

### Legal Status Flags

10. **EU member state–level legal status for harmine/harmaline**: Research agent has low confidence on country-specific status. Verification needed before publication.

11. **Australia-specific status for B. caapi and P. harmala**: Not confirmed via regulatory database. May require APVMA/TGA verification.

### Other Gaps

12. **Drug test detection**: No published studies on immunoassay cross-reactivity for smoked Changa alkaloids found.

13. **Contaminant/adulterant data**: Absent from literature for Changa specifically.

14. **Long-term use data**: No longitudinal studies on Changa or analogous smoked DMT+MAOI use exist.

15. **Brewing herbs beyond B. caapi and P. harmala**: Many Changa recipes include additional botanicals (wild dagga, blue lotus, passionflower, etc.) with unknown pharmacological contributions to the preparation. These are not quantified in any published study.